keyword
MENU ▼
Read by QxMD icon Read
search

Vortioxetine

keyword
https://www.readbyqxmd.com/read/29149828/vortioxetine-treatment-for-anxiety-disorder-a-meta-analysis-study
#1
Anne Yee, Chong Guan Ng, Loh Huai Seng
BACKGROUND: Vortioxetine is a multimodal antidepressant that has been developed for the treatment of major depressive and anxiety disorders. The aim of this review is to quantitatively synthesize all data of the efficacy, safety and tolerability of Vortioxetine in treating anxiety disorder. METHOD: Terms of "Vortioxetine" OR "LuAA21004" AND "anxiety" OR "fear" OR "panic" OR "phobia" were searched. A total of two phase II and five phase III clinical trials were found...
November 17, 2017: Current Drug Targets
https://www.readbyqxmd.com/read/29127931/efficacy-and-tolerability-of-different-doses-of-three-new-antidepressants-for-treating-major-depressive-disorder-a-prisma-compliant-meta-analysis
#2
Hairong He, Wei Wang, Jun Lyu, Jie Zheng, Liyang Guo, Xiaofang An, Yajuan Fan, Xiancang Ma
In last decade, the US FDA has approved three new antidepressants: vortioxetine, levomilnacipran, and vilazodone. Many studies have researched the effects of these antidepressants on major depressive disorder (MDD), but they have not determined the optimum dosage. This meta-analysis investigated the efficacies of these three drugs at different dosages in the treatment of MDD. The PubMed, Embase, Cochrane Library, psycINFO, and ClinicalTrials.gov databases were searched to identify relevant literature. The primary outcomes were efficacy [quantified as the change from baseline in total score on the Montgomery-Asberg Depression Rating Scale (MADRS)] and tolerability (discontinuations due to adverse events)...
October 21, 2017: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/29123483/impact-of-vortioxetine-on-synaptic-integration-in-prefrontal-subcortical-circuits-comparisons-with-escitalopram
#3
Shreaya Chakroborty, Thomas R Geisbush, Elena Dale, Alan L Pehrson, Connie Sánchez, Anthony R West
Prefrontal-subcortical circuits support executive functions which often become dysfunctional in psychiatric disorders. Vortioxetine is a multimodal antidepressant that is currently used in the clinic to treat major depressive disorder. Mechanisms of action of vortioxetine include serotonin (5-HT) transporter blockade, 5-HT1A receptor agonism, 5-HT1B receptor partial agonism, and 5-HT1D, 5-HT3, and 5-HT7 receptor antagonism. Vortioxetine facilitates 5-HT transmission in the medial prefrontal cortex (mPFC), however, the impact of this compound on related prefrontal-subcortical circuits is less clear...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29113521/efficacy-and-safety-of-vortioxetine-for-the-treatment-of-major-depressive-disorder-a-randomised-double-blind-placebo-controlled-study
#4
Jing Wang, Xi-Fang Liu, Chong Feng, Quan Bao, Hong-Ran Fu
OBJECTIVE: This study aimed to evaluate the efficacy and adverse events of vortioxetine for Chinese patients with major depressive disorder (MDD) over 10 weeks. METHODS: A total of 120 patients with MDD were randomly assigned to two groups that received vortioxetine 20 mg or placebo for 10 weeks. The outcomes were the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS), Hamilton Anxiety Rating Scale (HAM-A), Clinical Global Impressions-Improvement (CGI-I) scale, Sheehan Disability Scale (SDS) at Week 10, and the presence of adverse events...
November 7, 2017: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/29104073/acute-effects-of-vortioxetine-and-duloxetine-on-resting-state-functional-connectivity-in-the-awake-rat
#5
Pablo D Pérez, Zhiwei Ma, Christina Hamilton, Connie Sánchez, Arne Mørk, Alan L Pehrson, Christoffer Bundgaard, Nanyin Zhang
The antidepressant vortioxetine exerts its effects via modulation of several serotonin (5-HT) receptors and inhibition of the 5-HT transporter (SERT). Additionally, vortioxetine has beneficial effects on aspects of cognitive dysfunction in depressed patients. However, a global examination of the drug effect on brain network connectivity is still missing. Here we compared the effects of vortioxetine and a serotonin norepinephrine reuptake inhibitor, duloxetine, on resting-state functional connectivity (RSFC) across the whole brain in awake rats using a combination of pharmacological and awake animal resting-state functional magnetic resonance imaging (rsfMRI) techniques...
November 2, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/29102760/partial-inhibition-of-catecholamine-activity-and-enhanced-responsiveness-to-nmda-after-sustained-administration-of-vortioxetine
#6
Mohammad Ebrahimzadeh, Mostafa El Mansari, Pierre Blier
Vortioxetine is a multimodal drug that blocks serotonin (5-HT) reuptake and directly modulates 5-HT receptors. The effects of subacute and long-term administration of vortioxetine on various aspects of catecholamine and glutamate systems were investigated using single-unit extracellular recordings and microiontophoresis in the rat brain. The firing rate of dopamine (DA) neurons was significantly decreased (26%) after 14, but not 4 days of vortioxetine administration (vortioxetine-containing chow, 1.8 g/kg vortioxetine)...
November 13, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/29081307/efficacy-of-vortioxetine-in-working-patients-with-generalized-anxiety-disorder
#7
Michael Cronquist Christensen, Henrik Loft, Ioana Florea, Roger S McIntyre
BACKGROUND: Vortioxetine is an approved antidepressant that has also demonstrated positive effects on anxiety symptoms in subjects with generalized anxiety disorder (GAD). This post-hoc analysis evaluates the efficacy of vortioxetine in GAD subjects who are working and/or pursuing an education. METHODS: In study NCT00744627, 301 GAD subjects were randomized to vortioxetine 5 mg or placebo for 8 weeks. Efficacy measures included the Hamilton Anxiety Rating Scale (HAM-A) total score, response/remission, global functioning (Sheehan Disability Scale [SDS]), and quality of life (Short Form-36 Health Survey)...
October 30, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/29069110/vortioxetine-for-major-depressive-disorder-vasomotor-and-cognitive-symptoms-associated-with-the-menopausal-transition
#8
Marlene P Freeman, Laura J Cheng, Danna Moustafa, Abigail Davies, Alexandra Z Sosinsky, Betty Wang, Laura F Petrillo, Charlotte Hogan, Lee S Cohen
BACKGROUND: In a preliminary trial, we assessed the efficacy of vortioxetine for major depressive disorder (MDD) during the menopausal transition. Secondary outcomes included hot flashes (HFs), anxiety, and cognitive complaints. METHODS: Perimenopausal and early postmenopausal women with MDD (N = 27) received 8 weeks of open-label, flexible-dose treatment with vortioxetine. The Montgomery-Åsberg Depression Rating Scale (MADRS) was the primary outcome measure. Secondary measures included: HF frequency, the Greene Climacteric Scale (GCS), Menopause-Specific Quality of Life Questionnaire (MEN-QOL), Beck Anxiety Inventory (BAI), Cognitive and Physical Functioning Questionnaire (CPFQ), Digit Symbol Substitution Test (DSST), and Cogstate testing...
November 2017: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://www.readbyqxmd.com/read/29057467/vortioxetine-exerts-antiinflammatory-and-immunomodulatory-effects-on-human-monocytes-macrophages
#9
Maria Talmon, Silvia Rossi, Anna Pastore, Carlo Ignazio Cattaneo, Sandra Brunelleschi, Luigia Grazia Fresu
BACKGROUND AND PURPOSE: A crosstalk between the immune system and depression has been postulated, with a key role played by monocytes/macrophages and cytokines. In this paper we examined whether vortioxetine, a multimodal anti-depressive drug, was endowed of antiinflammatory and anti-oxidative activity, leading to immunomodulatory effects on human monocytes and macrophages. EXPERIMENTAL APPROACHES: Human monocytes were isolated from buffy coats and used as such or differentiated into M1 and M2 macrophages...
October 22, 2017: British Journal of Pharmacology
https://www.readbyqxmd.com/read/29053849/a-network-meta-analysis-comparing-effects-of-various-antidepressant-classes-on-the-digit-symbol-substitution-test-dsst-as-a-measure-of-cognitive-dysfunction-in-patients-with-major-depressive-disorder
#10
Bernhard T Baune, Mélanie Brignone, Klaus Groes Larsen
Background: Major depressive disorder (MDD) is a common condition that often includes cognitive dysfunction. A systematic literature review of studies and a network meta-analysis (NMA) were carried out to assess the relative effect of antidepressants on cognitive dysfunction in MDD. Methods: MEDLINE ®, Embase ®, Cochrane, CDSR, PsychINFO ® databases, clinical trial registries, and relevant conference abstracts were searched for randomised controlled trials (RCTs) assessing the effects of antidepressants/placebo on cognition...
October 19, 2017: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29053130/-multimodal-serotonergic-antidepressants
#11
D S Danilov
Based on the original literature, the author for the first time describes a history of selective serotonergic antidepressants simultaneously inhibiting the serotonin reuptake and directly interacting with serotonin receptors. A history of creation and introduction of their main representatives is presented. A history of investigation of their neurochemical activity is analyzed in details. The history of the evolution of their classifications is systemized. The data presented suggest the rationale for unifying all selective serotonergic antidepressants, simultaneously inhibiting the serotonin reuptake and directly interacting with serotonin receptors (trazodone, etoperidone, nefazodone, vilazodone, vortioxetine), in one group of 'multimodal serotonergic antidepressants'...
2017: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29040153/vortioxetine-and-aripiprazole-combination-in-treatment-resistant-obsessive-compulsive-disorder-a-case-report
#12
Domenico De Berardis, Luigi Olivieri, Francesco Nappi, Gabriella Rapini, Federica Vellante, Ilaria Matarazzo, Nicola Serroni, Massimo Di Giannantonio
No abstract text is available yet for this article.
October 16, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29035574/a-6-month-open-label-extension-study-of-vortioxetine-in-pediatric-patients-with-depressive-or-anxiety-disorders
#13
Robert L Findling, Adelaide S Robb, Melissa P DelBello, Michael Huss, Nora K McNamara, Elias H Sarkis, Russell E Scheffer, Lis H Poulsen, Grace Chen, Ole M Lemming, Philippe Auby
OBJECTIVES: In this 6-month open-label extension (OLE) of NCT01491035 (a 14-day, open-label, pharmacokinetic/safety lead-in study), the long-term safety and tolerability of vortioxetine (5-20 mg/day) were investigated in children and adolescents with a DSM-IV-TR™ diagnosis of depressive or anxiety disorder in the United States or Germany. The study also was designed to provide data to inform dose selection and titration in future pediatric studies with vortioxetine. METHODS: Safety evaluations included spontaneously reported adverse events (AEs), the Columbia Suicide Severity Rating Scale (C-SSRS), and the Pediatric Adverse Events Rating Scale (PAERS; clinician administered)...
October 16, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28953839/antidepressants-and-hyponatremia-in-a-patient-with-colectomy-a-case-report
#14
Madhavan Seshadri, Madhusudan Deepak Thalitaya, Tuno Simon, Catherine Odelola, Humphrey Enow
Antidepressants are routinely used by General Practitioners (GP) as well as Psychiatrists to treat Depression. They are tolerated well. However, in certain patient populations, they are associated with SIADH (Syndrome of Inappropriate Anti-Diuretic Hormone Secretion) and Hyponatremia. Various research studies have shown that all antidepressants are associated with Hyponatremia. Hyponatremia as a side effect of antidepressant therapy is more commonly seen in old age, chronic Kidney disease and Hypothyroidism...
September 2017: Psychiatria Danubina
https://www.readbyqxmd.com/read/28948135/pharmacological-management-of-anxiety-disorders-in-the-elderly
#15
Elizabeth A Crocco, Sindy Jaramillo, Caroline Cruz-Ortiz, Katherine Camfield
Anxiety disorders are common in the elderly. Additionally, anxiety symptoms often accompany co-morbid psychiatric, medical, as well as neurodegenerative diseases in the older population. Anxiety in the elderly, often accompanied by depression, can lead to worsening physical, cognitive and functional impairments in this vulnerable population. Antidepressants are considered first line treatment. Both SSRIs and SNRIs are efficacious and well-tolerated in the elderly. Some SSRIs are strong inhibitors of the cytochrome P450 hepatic pathway whereas others have less potential for drug interaction...
March 2017: Current Treatment Options in Psychiatry
https://www.readbyqxmd.com/read/28942181/novel-adverse-events-of-vortioxetine-a-disproportionality-analysis-in-usfda-adverse-event-reporting-system-database
#16
Viswam Subeesh, Hemendra Singh, Eswaran Maheswari, Elsa Beulah
BACKGROUND: Signal detection is one of the most advanced and emerging field in pharmacovigilance. It is a modern method of detecting new reaction (which can be desired or undesired) of a drug. It facilitates early adverse drug reaction detection which enables health professionals to identify adverse events that may not have been identified in pre-marketing clinical trials. Vortioxetine, the first mixed serotonergic antidepressant was initially approved by the US Food and Drug Administration (USFDA) on September 30, 2013 for the treatment of adults with Major Depressive Disorder (MDD)...
September 14, 2017: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/28941196/pharmacokinetics-safety-and-tolerability-of-vortioxetine-following-single-and-multiple-dose-administration-in-healthy-japanese-adults
#17
Kumi Matsuno, Koki Nakamura, Yutaka Aritomi, Akira Nishimura
Three phase 1 randomized single-center studies assessed the pharmacokinetics, safety, and tolerability of vortioxetine after single- and multiple-dose administration in healthy Japanese adults. Study 1 assessed the pharmacokinetics of vortioxetine after administration of single rising doses to men and multiple doses to men and women; study 2 evaluated vortioxetine pharmacokinetics in elderly adults; and study 3 assessed food effects on vortioxetine pharmacokinetics in healthy men. The primary end points included pharmacokinetic parameters of vortioxetine and incidence of adverse events (AEs)...
September 21, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28933261/pharmacological-treatment-of-cognitive-symptoms-in-major-depressive-disorder
#18
Zihang Pan, Radu C Grovu, Danielle S Cha, Nicole E Carmona, Mehala Subramaniapillai, Margarita Shekotikhina, Carola Rong, Yena Lee, Roger S McIntyre
: Background: Cognitive dysfunction is a core transdiagnostic domain of Major Depressive Disorder (MDD) and is a principal determinant of functional recovery. However, it has been insufficiently targeted within the current therapeutic framework for MDD. OBJECTIVE: To highlight these unmet cognitive needs in MDD. METHODS: An article search was conducted using PubMed from inception to November 2016: Major Depressive Disorder (and/or variant) was cross-referenced with the following terms: antidepressants, augmentation, cognition, cognitive deficits, cognitive dysfunction, functional outcomes, mechanism of action, and treatment...
September 18, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28881483/meta-analysis-risk-of-hyperhidrosis-with-second-generation-antidepressants
#19
Chad Beyer, Kiley Cappetta, Jessica A Johnson, Michael H Bloch
BACKGROUND: Our goal was to quantify the risk of hyperhidrosis associated with commonly used antidepressant agents and examine the impact of medication class, pharmacodynamics, and dose on risk of hyperhidrosis. METHODS: We conducted a PubMed search to identify all double-blind, randomized, placebo-controlled trials examining the efficacy of second-generation antidepressant medications in the treatment of adults with a depressive disorder, anxiety disorders, or obsessive-compulsive disorder...
September 7, 2017: Depression and Anxiety
https://www.readbyqxmd.com/read/28874391/%C3%A2-vortioxetine-for-acute-depression-in-adults
#20
(no author information available yet)
No abstract text is available yet for this article.
September 2017: Drug and Therapeutics Bulletin
keyword
keyword
22035
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"